• Center on Health Equity and Access
  • Clinical
  • Health Care Cost
  • Health Care Delivery
  • Insurance
  • Policy
  • Technology
  • Value-Based Care

Lessons from LIBRETTO-431 Trial in RET+ NSCLC


An overview of data presented at ESMO 2023 on the LIBRETTO-431 trial of selpercatinib in RET+ NSCLC.

This is a video synopsis/summary of a Post Conference Perspectives involving Patrick Forde, MBBCh.

Forde discusses results from the LIBRETTO-431 trial (NCT04194944) of selpercatinib in RET fusion–positive (RET+) non–small cell lung cancer (NSCLC). RET fusions occur in about 1% of NSCLC, predominantly in nonsmokers with nonsquamous histology. Selpercatinib is approved in advanced RET fusion–positive NSCLC based on improved efficacy over multikinase inhibitors.

LIBRETTO-431 randomly assigned patients with previously untreated advanced RET fusion–positive NSCLC to platinum doublet chemotherapy plus pembrolizumab or selpercatinib. Selpercatinib significantly improved progression-free survival from 11.2 to 24.8 months, with an HR of 0.46 favoring selpercatinib. Response rates also improved by 18% with selpercatinib.

Forde states this confirmatory trial supports selpercatinib as the appropriate first-line therapy for RET fusion–positive advanced NSCLC. He notes some debate exists over whether such randomized trials are needed when targeted therapies show efficacy in single-arm trials but thinks this study confirms current practice. Confirmatory randomized trials with rare oncogenic drivers may not be possible or feasible to conduct, but this study provides definitive evidence to test for and treat RET fusion–positive disease with selpercatinib.

Video synopsis is AI-generated and reviewed by AJMC® editorial staff.

Related Videos
Mona Shahriari, MD, assistant clinical professor of dermatology at Yale University and associate director of clinical trials at Central Connecticut Dermatology
Video 7 - "Future Opportunities in Genitourinary Cancers"
Video 6 - "LITESPARK-003 Trial Insights: Updates from ESMO 2023"
Video 5 - "Key Highlights from EV-302 Study at ESMO 2023"
Siamak Daneshmand, MD, discusses the results of SunRISe-1 study of TAR-200, an intravesical drug delivery system, in patients with BCG-unresponsive HR NMIBC from ESMO 2023.
Dr Jennifer Brown
Related Content
© 2023 MJH Life Sciences
All rights reserved.